|
EP2558128B1
(en)
|
2010-04-14 |
2016-12-21 |
Roger Williams Medical Center |
Methods and compositions for treating hiv
|
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
US9402865B2
(en)
*
|
2011-01-18 |
2016-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
WO2014055442A2
(en)
*
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
WO2014055657A1
(en)
*
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
EP2906684B8
(en)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
EP4303232A3
(en)
|
2013-02-15 |
2024-04-17 |
The Regents of The University of California |
Chimeric antigen receptor and methods of use thereof
|
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
PL3546572T3
(pl)
|
2013-05-13 |
2024-07-22 |
Cellectis |
Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
|
|
CN105593362B
(zh)
*
|
2013-09-23 |
2021-09-10 |
威尔逊沃夫制造公司 |
遗传修饰动物细胞的改进方法
|
|
CN103589742A
(zh)
*
|
2013-11-07 |
2014-02-19 |
申峰 |
嵌合体抗原受体胞内段的基因及其编码蛋白
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2015092024A2
(en)
*
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
|
EP3656864A1
(en)
*
|
2014-02-14 |
2020-05-27 |
Board of Regents, The University of Texas System |
Chimeric antigen receptors and methods of making
|
|
GB201405845D0
(en)
*
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
CA2945320A1
(en)
*
|
2014-04-10 |
2015-10-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Drug regulated transgene expression
|
|
KR20160145802A
(ko)
*
|
2014-04-23 |
2016-12-20 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
|
|
LT3134432T
(lt)
|
2014-04-25 |
2020-04-10 |
Bluebird Bio, Inc. |
Mnd promotorius chimerinių antigenų receptoriams
|
|
NZ725201A
(en)
|
2014-04-25 |
2018-05-25 |
Bluebird Bio Inc |
Improved methods for manufacturing adoptive cell therapies
|
|
DK3166968T3
(da)
*
|
2014-05-02 |
2021-12-06 |
Univ Pennsylvania |
Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
|
|
SI3151672T1
(sl)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
MX2017001229A
(es)
*
|
2014-07-29 |
2017-05-01 |
Pfizer |
Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
WO2016033331A1
(en)
|
2014-08-28 |
2016-03-03 |
Bioatla, Llc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
CN107109438B
(zh)
*
|
2014-11-05 |
2021-09-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
EA036379B1
(ru)
|
2014-12-12 |
2020-11-02 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы к bcma
|
|
BR112017013176A2
(en)
*
|
2014-12-19 |
2018-05-15 |
Dana-Farber Cancer Institute Inc. |
chimeric antigen receptors and methods for using them
|
|
CA3197849A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016138034A1
(en)
|
2015-02-24 |
2016-09-01 |
The Regents Of The University Of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
KR20260048600A
(ko)
|
2015-03-27 |
2026-04-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
변형된 t 세포 및 이의 제조 및 사용 방법
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
AU2016261864B2
(en)
*
|
2015-05-13 |
2022-05-26 |
Csl Behring Gene Therapy, Inc. |
Bio-production of lentiviral vectors
|
|
CN107995913B
(zh)
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
IL295224B2
(en)
|
2015-05-28 |
2025-07-01 |
Kite Pharma Inc |
Methods of conditioning patients for t cell therapy
|
|
MX388325B
(es)
|
2015-05-28 |
2025-03-19 |
Kite Pharma Inc |
Metodos de diagnostico para tratamiento con linfocitos t.
|
|
US10071118B2
(en)
*
|
2015-07-16 |
2018-09-11 |
Prospect Charactercare Rwmc, Llc |
Compositions and methods for treating peritoneal cancers
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
WO2017027291A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
EP3364969A4
(en)
|
2015-10-20 |
2019-07-10 |
Kite Pharma, Inc. |
METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY
|
|
EP3368051B1
(en)
|
2015-10-30 |
2026-04-15 |
Children's National Medical Center |
Generating hpv antigen-specific t cells from a naive t cell population
|
|
CN105331585A
(zh)
|
2015-11-13 |
2016-02-17 |
科济生物医药（上海）有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
|
SI3377618T1
(sl)
*
|
2015-11-19 |
2021-02-26 |
Novartis Ag |
Pufri za stabilizacijo lentivirusnih pripravkov
|
|
EP3377523A4
(en)
*
|
2015-11-19 |
2019-06-19 |
The Regents of The University of California |
CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
|
|
EP3708587B1
(en)
|
2015-11-27 |
2024-05-22 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
GB201522097D0
(en)
|
2015-12-15 |
2016-01-27 |
Cellular Therapeutics Ltd |
Cells
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
JP7068169B2
(ja)
|
2016-01-08 |
2022-05-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
条件付活性ヘテロ二量体ポリペプチド及びその使用方法
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
PT3436079T
(pt)
|
2016-04-01 |
2021-10-06 |
Kite Pharma Inc |
Recetores de antigénios quiméricos e de células t e métodos de uso
|
|
KR20200068750A
(ko)
|
2016-04-01 |
2020-06-15 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
|
CN109414455B
(zh)
|
2016-04-01 |
2023-01-20 |
凯德药业股份有限公司 |
Bcma结合分子及其使用方法
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
CN109414512A
(zh)
|
2016-04-22 |
2019-03-01 |
科济生物医药（上海）有限公司 |
用于细胞免疫疗法的组合物和方法
|
|
WO2017186121A1
(zh)
*
|
2016-04-26 |
2017-11-02 |
科济生物医药（上海）有限公司 |
一种改善免疫应答细胞功能的方法
|
|
CN116751298A
(zh)
|
2016-05-13 |
2023-09-15 |
生物蛋白有限公司 |
抗ror2抗体、抗体片段和它们的免疫缀合物以及其用途
|
|
GB2567093A
(en)
|
2016-07-15 |
2019-04-03 |
Viracta Therapeutics Inc |
Histone deacetylase inhibitors for use in immunotherapy
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CA3037518A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
WO2018075820A2
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
CA3040296A1
(en)
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
KR20240005168A
(ko)
|
2016-11-04 |
2024-01-11 |
2세븐티 바이오, 인코포레이티드 |
항-bcma car t 세포 조성물
|
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CN110291200B
(zh)
|
2016-12-12 |
2024-05-14 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN106749681A
(zh)
*
|
2017-02-10 |
2017-05-31 |
河南大学淮河医院 |
靶向人FRα的基因工程化NKT细胞及其制备方法和应用
|
|
PT3583129T
(pt)
|
2017-02-14 |
2021-12-14 |
Kite Pharma Inc |
Moléculas de ligação a cd70 e seus métodos de uso
|
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための組成物および方法
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
EP3596114A2
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
JP2020511144A
(ja)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
|
|
PT3596116T
(pt)
|
2017-03-16 |
2023-12-04 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de pd-l1 variante e suas utilizações
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
TW201900672A
(zh)
*
|
2017-03-27 |
2019-01-01 |
瑞士商赫孚孟拉羅股份公司 |
改良之抗原結合受體型式
|
|
EP3490605B1
(en)
|
2017-04-01 |
2023-06-07 |
AVM Biotechnology, LLC |
Replacement of cytotoxic preconditioning before cellular immunotherapy
|
|
AU2018250148B2
(en)
|
2017-04-03 |
2021-09-23 |
Kite Pharma, Inc. |
Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
|
|
WO2018195339A1
(en)
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
SG10201912400VA
(en)
|
2017-04-24 |
2020-02-27 |
Kite Pharma Inc |
Humanized antigen-binding domains against cd19 and methods of use
|
|
SG10202112528QA
(en)
*
|
2017-05-12 |
2021-12-30 |
Jackson Lab |
Nsg mice lacking mhc class i and class ii
|
|
KR20200015717A
(ko)
|
2017-06-09 |
2020-02-12 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
|
|
US12144825B2
(en)
|
2017-06-30 |
2024-11-19 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
AU2018313950A1
(en)
*
|
2017-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
KR20230052312A
(ko)
*
|
2017-09-15 |
2023-04-19 |
카이트 파마 인코포레이티드 |
관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
|
|
WO2019060425A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
|
|
CA3076099A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
Linkers for chimeric antigen receptors
|
|
KR102813968B1
(ko)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
CA3084470A1
(en)
|
2017-10-18 |
2019-04-25 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
|
SMT202600062T1
(it)
|
2017-10-18 |
2026-03-09 |
Alpine Immune Sciences Inc |
Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati
|
|
JP7585034B2
(ja)
|
2017-10-18 |
2024-11-18 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
|
US11712026B2
(en)
|
2017-10-18 |
2023-08-01 |
The Jackson Laboratory |
Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
|
|
CN111683962B
(zh)
|
2017-11-10 |
2025-05-16 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向肿瘤抗原的嵌合抗原受体
|
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
|
SG11202006148UA
(en)
|
2018-01-03 |
2020-07-29 |
Alpine Immune Sciences Inc |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
US12491153B2
(en)
|
2018-01-03 |
2025-12-09 |
Qu Biologics Inc. |
Innate targeting of adoptive cellular therapies
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
BR112020014446A2
(pt)
|
2018-01-15 |
2020-12-29 |
Pfizer Inc. |
Métodos para administrar imunoterapia de receptor de antígeno quimérico em combinação com agonista de 4-1bb
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞の使用方法
|
|
CN112534044A
(zh)
|
2018-02-16 |
2021-03-19 |
凯德药业股份有限公司 |
经修饰的多能干细胞及制备和使用方法
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
CN115925952A
(zh)
|
2018-03-13 |
2023-04-07 |
东莞凡恩世生物医药有限公司 |
抗叶酸受体1抗体及其用途
|
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
|
TWI784324B
(zh)
|
2018-04-12 |
2022-11-21 |
美商凱特製藥公司 |
利用腫瘤微環境之特性之嵌合受體t細胞治療
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
KR102544086B1
(ko)
|
2018-06-01 |
2023-06-16 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 t 세포 요법
|
|
CN112423793A
(zh)
|
2018-06-05 |
2021-02-26 |
宾夕法尼亚大学董事会 |
肌肉特异性激酶嵌合自身抗体受体细胞的组合物和方法
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
US20210269501A1
(en)
*
|
2018-06-25 |
2021-09-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
|
|
CN112955548B
(zh)
|
2018-07-09 |
2023-11-24 |
普众发现医药科技(上海)有限公司 |
叶酸受体α特异性抗体
|
|
SG11202101014XA
(en)
|
2018-08-02 |
2021-02-25 |
Kite Pharma Inc |
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
|
|
CN110819703A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞安全性的方法
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
|
AU2019345151B2
(en)
|
2018-09-19 |
2025-04-17 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant CD80 fusion proteins and related constructs
|
|
EP3856763A1
(en)
|
2018-09-28 |
2021-08-04 |
Massachusetts Institute of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
|
CN112996809A
(zh)
*
|
2018-10-10 |
2021-06-18 |
酵活有限公司 |
结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
|
|
CN111197032A
(zh)
*
|
2018-11-16 |
2020-05-26 |
上海斯丹赛生物技术有限公司 |
嵌合抗原受体细胞分泌治疗剂
|
|
EP3883585A4
(en)
*
|
2018-11-20 |
2022-12-14 |
Innovative Cellular Therapeutics Holdings, Ltd. |
MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
JP7278379B2
(ja)
|
2018-11-29 |
2023-05-19 |
ヴィネティ インク． |
集中型及び分散型の個別化医薬プラットフォーム
|
|
US12227551B2
(en)
|
2018-12-11 |
2025-02-18 |
Obsidian Therapeutics, Inc. |
Membrane bound IL12 compositions and methods for tunable regulation
|
|
KR102840400B1
(ko)
|
2018-12-12 |
2025-08-04 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
CN109796535B
(zh)
*
|
2019-01-30 |
2022-11-15 |
重庆福美干细胞生物科技发展有限公司 |
靶向叶酸受体α的嵌合抗原受体及其在制备预防或治疗恶性肿瘤药物中的用途
|
|
US11321652B1
(en)
|
2019-02-20 |
2022-05-03 |
Vineti Inc. |
Smart label devices, systems, and methods
|
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
|
JP7654557B2
(ja)
*
|
2019-03-27 |
2025-04-01 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
|
|
US20200384027A1
(en)
|
2019-05-03 |
2020-12-10 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
|
CN121204097A
(zh)
*
|
2019-05-13 |
2025-12-26 |
宾夕法尼亚大学董事会 |
乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法
|
|
EP3973072A1
(en)
|
2019-05-23 |
2022-03-30 |
Vogelsang, Matjaz |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
|
EP3983537A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
EP3983538A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
WO2020257823A2
(en)
|
2019-06-21 |
2020-12-24 |
Kite Pharma, Inc. |
TGF-β RECEPTORS AND METHODS OF USE
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
|
KR20220054383A
(ko)
|
2019-09-03 |
2022-05-02 |
알로젠 테라퓨틱스 인코포레이티드 |
T 세포 요법을 위한 t 세포를 제조하는 방법
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
EP4041297A4
(en)
|
2019-10-11 |
2024-02-28 |
The Trustees of The University of Pennsylvania |
COMPOSITIONS AND METHODS FOR TARGETING CD13 AND TIM-3 WITH CAR-T CELLS FOR TREATING ACUTE MYELOID LEUKEMIA
|
|
US20240122978A1
(en)
*
|
2019-10-16 |
2024-04-18 |
Umoja Biopharma, Inc. |
Retroviral vector for univeral receptor therapy
|
|
IL292665B2
(en)
|
2019-11-06 |
2026-02-01 |
Kite Pharma Inc |
Chimeric antigen receptor T cell therapy
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
WO2021123832A1
(en)
|
2019-12-20 |
2021-06-24 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
KR20240096884A
(ko)
|
2020-03-10 |
2024-06-26 |
매사추세츠 인스티튜트 오브 테크놀로지 |
조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
|
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
AU2021308702A1
(en)
|
2020-07-17 |
2023-03-16 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
KR20230084470A
(ko)
|
2020-08-14 |
2023-06-13 |
카이트 파마 인코포레이티드 |
면역 세포 기능의 향상
|
|
EP4200437A4
(en)
*
|
2020-08-18 |
2025-07-23 |
Delfi Diagnostics Inc |
METHODS AND SYSTEMS FOR SIZE-BASED DENSITIES OF CELL-FREE DNA FRAGMENTS TO ASSESS CANCER
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
JP2023542539A
(ja)
|
2020-09-24 |
2023-10-10 |
ザ ジャクソン ラボラトリー |
免疫細胞療法を評価するためのヒト化マウスモデル
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
AU2021410635A1
(en)
|
2020-12-24 |
2023-06-29 |
Kite Pharma, Inc. |
Prostate cancer chimeric antigen receptors
|
|
WO2022150582A1
(en)
|
2021-01-10 |
2022-07-14 |
Kite Pharma, Inc. |
T cell therapy
|
|
TW202241469A
(zh)
|
2021-02-20 |
2022-11-01 |
美商凱特製藥公司 |
免疫療法
|
|
IL305571A
(en)
|
2021-03-11 |
2023-10-01 |
Kite Pharma Inc |
Improving the function of immune system cells
|
|
CN112794911B
(zh)
*
|
2021-04-14 |
2021-08-03 |
上海偌妥生物科技有限公司 |
人源化抗叶酸受体1抗体及其应用
|
|
AU2022259428A1
(en)
|
2021-04-16 |
2023-10-26 |
Kite Pharma, Inc. |
Taci/bcma dual binding molecules
|
|
CN117203328A
(zh)
|
2021-04-27 |
2023-12-08 |
武田药品工业株式会社 |
重组抗原呈递细胞
|
|
EP4337227A2
(en)
|
2021-05-14 |
2024-03-20 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
|
IL308696A
(en)
|
2021-05-24 |
2024-01-01 |
Kite Pharma Inc |
Nkg2d-based chimeric antgen receptor
|
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
WO2022261061A1
(en)
|
2021-06-08 |
2022-12-15 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
|
EP4355340A4
(en)
|
2021-06-16 |
2025-05-21 |
Instil Bio, Inc. |
RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
|
|
CN115572715A
(zh)
*
|
2021-06-21 |
2023-01-06 |
复星凯特生物科技有限公司 |
一种靶向folr1和her2双打靶点car t的制备及应用
|
|
WO2023278553A1
(en)
|
2021-07-01 |
2023-01-05 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
|
JP2024525485A
(ja)
|
2021-07-02 |
2024-07-12 |
カイト ファーマ インコーポレイテッド |
細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法
|
|
EP4370213A4
(en)
|
2021-07-16 |
2025-06-04 |
Instil Bio (Uk) Limited |
Chimeric molecules for targeted costimulation for adoptive cell therapy
|
|
US11615874B1
(en)
|
2021-09-30 |
2023-03-28 |
Vineti Inc. |
Personalized medicine and therapies platform
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
TW202334400A
(zh)
|
2021-12-30 |
2023-09-01 |
美商Ｔｒ１Ｘ股份有限公司 |
表現il-10及嵌合抗原受體之cd4+ t細胞及其用途
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20230296610A1
(en)
|
2022-02-15 |
2023-09-21 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
|
AU2023282907A1
(en)
|
2022-06-09 |
2024-11-14 |
Kite Pharma, Inc. |
Methods of preparing lymphocytes for cell therapy
|
|
JP2025526690A
(ja)
|
2022-08-10 |
2025-08-15 |
武田薬品工業株式会社 |
免疫原性が低い改変細胞
|
|
CN120239746A
(zh)
|
2022-09-19 |
2025-07-01 |
图恩疗法股份有限公司 |
用于调节t细胞功能的组合物、系统和方法
|
|
KR20250097844A
(ko)
|
2022-10-28 |
2025-06-30 |
카이트 파마 인코포레이티드 |
면역요법의 효능 향상 및 지속적인 반응
|
|
WO2024092227A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy
|
|
KR20250162836A
(ko)
|
2023-03-17 |
2025-11-19 |
카이트 파마 인코포레이티드 |
종양 미세환경이 면역요법의 효능에 미치는 영향
|
|
WO2024206549A2
(en)
*
|
2023-03-29 |
2024-10-03 |
Cellicure, Inc. |
Engineered immune cells and use thereof
|
|
TW202506996A
(zh)
|
2023-04-27 |
2025-02-16 |
日商武田藥品工業股份有限公司 |
擴增ｃｄ５６＋／ｃｄ３－細胞之方法
|
|
CN121909284A
(zh)
|
2023-07-31 |
2026-04-21 |
图恩疗法股份有限公司 |
用于调节il-2基因表达的组合物和方法
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025096517A1
(en)
|
2023-11-01 |
2025-05-08 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy efficacy
|
|
WO2025188561A1
(en)
|
2024-03-04 |
2025-09-12 |
Kite Pharma, Inc. |
Predictive markers for immunotherapy
|
|
WO2026015450A1
(en)
|
2024-07-06 |
2026-01-15 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
WO2026069206A1
(en)
|
2024-09-25 |
2026-04-02 |
Takeda Pharmaceutical Company Limited |
Hypoimmunogenic modified gamma delta t cells
|